AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01074073 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lurasidone HCl
Description: lurasidone HCl 40 mg tablets administered orally as three tablets (120 mg) once a day (QD).~Lithium 300 mg capsules administered orally as two capsules (600 mg) twice a day (BID).~On dosing days, breakfast will be served 30 minutes prior to the planned dosing time. Patients must consume the breakfast within 30 minutes or less. Dosing will take place 30 minutes after the start of breakfast.
Study NCT03019887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine
Study NCT01389986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gum chewing
Description: Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
Study NCT01899430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Study NCT01899430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Study NCT01935544 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Botulinum toxin injection
Study NCT02171026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Study NCT02171026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Study NCT02171026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone
Study NCT03578107 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: improvement of quality of stroke care
Description: 1. hospital tool kits for quality improvement of reperfusion therapy ;~2. organizational stakeholder and opinion leader meetings;~3. data monitoring and feedback reports；~4. webinar for hospital teams
Study NCT01025557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Dietary treatments with beverages
Study NCT03314610 — intervention group
Intervention type: OTHER
Intervention: Gait speed
Description: No intervention, only propose water and wait for need to void
Study NCT03153501 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CT-guided Abrams needle biopsy, US-guided cutting needle, medical thoracoscopy
Study NCT02433912 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Test - Laterally positioned flap
Description: Laterally positioned flap. Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days. chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days.
Study NCT02433912 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control-Coronally positioned flap
Description: Coronally positioned flap. Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days. chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days.
Study NCT02433912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 750 mg paracetamol
Description: Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days
Study NCT02433912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 750 mg paracetamol
Description: Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days
Study NCT02433912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine gluconate
Description: chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days
Study NCT02433912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorhexidine gluconate
Description: chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days
Study NCT02733744 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Description: FMT will be given through the ingestion of 30 capsules (15 capsules daily x 2 consecutive days)
Study NCT00895362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Starting dose 100 mg by mouth 1 time every day for 28-day cycle (Pediatric starting dose 50 mg).
Study NCT00895362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Loading dose of 200 mg/m\^2 (maintenance 125 mg/m\^2) by vein 1 day every week of 28-day cycle, on Days 1, 8, 15 and 22. First dose given over 2 hours and over 1 hour each subsequent time.
Study NCT02877576 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of mixed intracerebral electrodes
Description: 5 macro electrodes with micro electrodes are implanted in internal temporal structures (amygdala, anterior and posterior hippocampus, rhinal cortex, posterior para-hippocampal gyrus).~Each electrode has 8 microcontacts, each recording the activity of 0 to 3 neurons (activity of 0 to 120 neurons/patient).
Study NCT02877576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face detection
Description: Visualization of images of 60 unknown faces and 60 objects that are not faces (object, house, scene, animal, plant, word, letter...). Each image is showed for 500 ms and separated from following image by black screen of 1500 ms. In order to keep patient attention on image, patient will be asked to push a button at color change of fixation cross in the centre of image.
Study NCT02877576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face individualization
Description: Visualization of images of celebrities (persons known by patient), showed randomly. Each image is showed for 500 ms and separated from following image by black screen of 1500 ms. In order to keep patient attention on image, patient will be asked to push a button at color change of fixation cross in the centre of image.~Several celebrities are showed, with for each the presentation of 60 images different from that celebrity. 1 to 3 celebrities are showed (60 to 180 total images).
Study NCT02065492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Chelation
Description: This will comprise of standard chelation drugs (Deferasirox or Deferoxamine or Combination of Deferoxamine and Deferiprone).The dosage and drug used will depend on ferritin levels and individual requirement, as determined by the treating hematologist and will be in accordance with the Iron chelation guidelines from Pakistan Thalassemia Society.
Study NCT02065492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Chelation
Description: This will comprise of standard chelation drugs (Deferasirox or Deferoxamine or Combination of Deferoxamine and Deferiprone).The dosage and drug used will depend on ferritin levels and individual requirement, as determined by the treating hematologist and will be in accordance with the Iron chelation guidelines from Pakistan Thalassemia Society.
Study NCT02065492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: doses of 0.2 to 0.25 mg/kg/day PO would be given during this trial
Study NCT02625350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instant noodle without soup
Description: First, fasting blood glucose was measured. Then, subjects consumed the sample (instant noodle without soup) and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
Study NCT02625350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instant noodle with soup
Description: First, fasting blood glucose was measured. Then, subjects consumed the sample (instant noodle with soup) and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
Study NCT02625350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose reference
Description: First, fasting blood glucose was measured. Then, subjects consumed the glucose reference and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
Study NCT04357561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise group (Schroth best practice)
Description: Exercise program will be structured with scoliosis specific exercises (schroth best practice). Schroth best pratice is a pattern spesific scoliosis rehabilitation concept which aimes active self correction during curve pattern specific curve activities of daily life. Exercises for rotational breathing, everyday activities, spinal mobilization and corrective exercises will be specified based on the curve type and applied under the supervision of a physiotherapist.
Study NCT03068897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metaxalone
Description: Metaxalone 400-800mg
Study NCT03068897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tizanidine
Description: Tizanidine 2-4mg
Study NCT03068897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: Baclofen 10-20mg
Study NCT03068897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: Ibuprofen
Study NCT03068897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: Ibuprofen
Study NCT03068897 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational intervention
Description: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.
Study NCT03068897 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Educational intervention
Description: Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.
Study NCT00511758 — intervention group
Intervention type: PROCEDURE
Intervention: Digital Imaging
Description: Images of the cervix will be taken using different types of light and compared with the colposcopy procedure.
Study NCT00447798 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevention Care Advocate
Description: Prevention Care Advocate: 8 Session intervention combining cognitive-behavioral skill building \& strengths based case management
Study NCT04862559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovaCross
Description: A device that is intended to asisst interventional cardiologists during catheterization to cross and open coronary chronic total occlusions
Study NCT04406103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleepwell
Description: Information intended to support capability, opportunity, and motivation for stopping sleeping pill use and using non-pharmacological approaches to managing insomnia.
Study NCT04406103 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Empower
Description: Information intended to support capability, opportunity, and motivation for stopping sleeping pill use and using non-pharmacological approaches to managing insomnia.
Study NCT03801928 — intervention group
Intervention type: DRUG
Intervention: Inflectra
Description: The study plans to recruit 300 subjects in the United States and Canada initiating or switching to treatment with INFLECTRA over an 8 month period. The decision to start INFLECTRA will be entirely a clinical decision made by the participating physician irrespective of this study.
Study NCT00465608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol
Description: propranolol by mouth (per os)
Study NCT03102294 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: inspiratory muscle training
Description: inspiratory muscle training with 50% of MIP
Study NCT03102294 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo training
Description: placebo training with PowerBreathe (without inspiratory load)
Study NCT02782845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: The choice of CT will be as per standard of care and protocol does not specify any particular CT drug.
Study NCT02782845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunochemotherapy
Description: The choice of ICT will be as per standard of care and protocol does not specify any particular ICT drug.
Study NCT02782845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Pegfilgrastim will be administered at a fixed dose of 6 mg subcutaneously 24 hours after the last dose of CT or ICT is received for 6 cycles.
Study NCT05320484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Pilates Exercises
Description: clinical pilates exercises methods applied to the 1st group, classical posture exercises methods to the 2nd group for 3 days / week for 6 weeks.
Study NCT05320484 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Classic Posture exercise
Description: clinical pilates exercises methods applied to the 1st group, classical posture exercises methods to the 2nd group for 3 days / week for 6 weeks.
Study NCT00292526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: enalapril orally administered
Study NCT02261207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib will be administered at the dose of 5mg twice a day, continuously. Treatment will be continued till evidence of progression, or toxicities or patient withdrawal.
Study NCT00968773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rebound HRD
Description: Laparoscopic TEP inguinal hernia repair using the Rebound HRD and no fixation
Study NCT00968773 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard hernia mesh (VitaMesh)
Description: Laparoscopic TEP inguinal hernia repair using standard hernia mesh with fixation
Study NCT02862977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoprofen and cyclobenzaprine association with caffeine
Description: The patient will take 2 tablets (combination of ketoprofen and cyclobenzaprine and caffeine), oral, per day, each 12h
Study NCT02862977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclobenzaprine with caffeine
Description: The patient will take 2 tablets (combination of cyclobenzaprine and caffeine), oral, per day, each 12h
Study NCT02737319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 40 mg of rosuvastatin before angioplasty
Study NCT00484783 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Natural Orifice Transluminal Endoscopic Surgery (NOTES)
Description: Patients will have the standard laparoscopic procedure and the NOTES procedure will be added. The surgical procedure will require two operating teams: one led by a laparoscopic surgeon, the other by an endoscopic surgeon. During the usual course of the surgery, the flexible endoscope will be passed through the mouth urethra top gain access to the peritoneal cavity.
Study NCT00484783 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Natural Orifice Translumenal Endoscopic Surgery (NOTES)
Description: chart review of historical data from control group
Study NCT02177630 — intervention group
Intervention type: OTHER
Intervention: Endomyocardial Biopsy
Study NCT01916486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: The EX Program will provide objective progression in the guided exercises of each participant.
Study NCT04580121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7283420
Description: RO7283420 at RP2D will be administered by IV infusion or SC injection as per dosing schedule determined in Part B.
Study NCT04580121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered as an IV infusion 8 mg/kg (for participants with a weight of 30 kg and above) and 12 mg/kg (for participants with a weight of less than 30 kg). Tocilizumab will be given as rescue medication.
Study NCT04580121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Dasatinib 100 mg film-coated tablets will be administered daily until symptom resolution (up to 100 mg twice daily \[BID\] for a maximum 3 days); orally. Dasatinib will be given as rescue medication.
Study NCT04580121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg IV of dexamethasone will be administered as pre-medication at least 60 minutes prior to the all RO7283420 infusions or injections during cycle 1.
Study NCT04580121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol/acetaminophen
Description: 500 or 1000 mg of paracetamol/acetaminophen will be administered orally or by IV as pre-medication at least 30 minutes prior to each RO7283420 infusion or injection.
Study NCT04580121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 25 mg or 50 mg of diphenhydramine will be administered orally or by IV as pre-medication at least 30 minutes prior to each RO7283420 infusion or injection.
Study NCT01781819 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ARFI SVI Ultrasound Imaging
Description: Following a clinical renal ultrasound scan, the research scan using the ultrasound based acoustic radiation force impulse, or shear wave velocity imaging will be performed using standard approved ultrasound machines and transducers. This imaging will take approximately 5 to 10 minutes to complete.
Study NCT04566341 — intervention group
Intervention type: DEVICE
Intervention: OCT - TCE
Description: Participants will be asked to swallow the TCE. They may use mild numbing spray, and lubrication spray to help swallowing. Imaging will be conducted once the TCE is past the pharynx. We will advance the TCE until the stomach and then slowly pull the TCE back up the esophagus. This may be repeated twice.
Study NCT02178280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: liver transplantation combined with neoadjuvant therapy
Description: liver transplantation combined with neoadjuvant radiochemotherapy
Study NCT03861481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Description: Subjects will receive rozanolixizumab in a specified sequence during the treatment period.
Study NCT03861481 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo in a specified sequence during the treatment period.
Study NCT01029158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Juvista (Avotermin)
Description: 250 ng, twice, intradermal injection, standard formulation
Study NCT01029158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RN1006 (Avotermin)
Description: 250 ng, intradermal injection, twice
Study NCT01029158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RN1006 (Avotermin)
Description: 205 ng, Intradermal injection, once
Study NCT01029158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RN1006 (Avotermin)
Description: 500ng, intradermal injection, once
Study NCT01029158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Juvista (Avotermin)
Description: 250 ng, intradermal injection, twice
Study NCT01029158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Juvista (Avotermin)
Description: 500 ng, intradermal injection, once
Study NCT01029158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RN1006 (Avotermin)
Description: 500 ng, intradermal injection, twice
Study NCT01029158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT01916486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complex mental and social activities
Description: The Cog-Plus Program will engage participants in activities promoting cognitive function and socialization.
Study NCT02409602 — intervention group
Intervention type: OTHER
Intervention: Doppler ultrasonographic examination
Description: Dorsal clitoral artery Doppler ultrasonographic examinations will be performed regularly in 3rd and 6th months after delivery, in order to evaluate the possible effects of BIIAL on clitoral blood flow.
Study NCT02416115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramosetron
Description: Ramosetron was given iv.
Study NCT02416115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: Ramosetron was given iv.
Study NCT02416115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Description: Naloxone added to PCA was given iv.
Study NCT02416115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Naloxone added to PCA was given iv.
Study NCT02416115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: Saline was given iv.
Study NCT01916486 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control: stretching and relaxation program
Description: The CON Program consist of stretches, deep breathing and relaxation techniques, general posture education, and general core control exercises in the sitting position.
Study NCT03961243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YUVA-GT-F901
Description: Lentiviral factor IX gene modified autologous hematopoietic and mesenchymal stem cells
Study NCT02416115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine in the PCA was given iv.
Study NCT00531141 — intervention group
Intervention type: OTHER
Intervention: examination only
Description: OCT performed twice